NEWS: 公告在東京證券交易所JASDAQ標準市場新上市

表紙
市場調查報告書

敗血症:機會評估,流行病學研究,市場動態和渠道分析(2020年下半年)

Sepsis - Opportunity Assessments, Epidemiological Studies, Market Dynamics and Pipeline Analytics, H2 2020

出版商 GervanoRA Data Services LLP 商品編碼 963779
出版日期 內容資訊 英文 179 Pages
商品交期: 最快1-2個工作天內
價格
敗血症:機會評估,流行病學研究,市場動態和渠道分析(2020年下半年) Sepsis - Opportunity Assessments, Epidemiological Studies, Market Dynamics and Pipeline Analytics, H2 2020
出版日期: 2020年10月08日內容資訊: 英文 179 Pages
簡介

該報告調查了敗血症市場,並提供了有關流行病學,市場機會,增長和限制因素,價格,策略,管道產品分析,競爭狀況,主要公司概況等信息。

目錄

第1章簡介

第2章執行摘要

  • 報告摘要
  • 敗血症競爭空間中的重要事件
  • 主要調查結果報告
    • 生長因素
    • 抑制因素
    • 市場機會
  • 化膿性競爭的市場動態
    • 未滿足的需求和市場需求
    • 未滿足需求的管理途徑(ROA)和市場需求
    • 區域未滿足的需求和市場需求
    • 新藥定價和定價策略

第3章管道分析的前景

  • 管道分析的比較快照
    • 按開發階段
    • 按地區
    • 按ROA
    • 按醫藥品
    • 按作用機制
    • 按分子類型
    • 按分子靶標
    • 按公司類型

第4章敗血症治療概述

  • 簡介
  • 敗血症治療:發展評估
  • 敗血症的治療範圍
  • 治療算法和準則
  • 流行病學研究

第5章市場動態

  • 交易(合併/收購/合作)
    • 按交易類型進行交易分析
    • 每年處理一次分析
    • 公司主動交易分析

第6章化膿性管線藥物的專利分析

  • 區域專利分析
  • 專利到期的專利分析
  • 特殊津貼和擴展專利分析

第7章敗血症的流水線藥物分析

  • 按開發階段進行的管線藥物分析
    • 第三階段管道藥物
    • 第二階段管道藥物
    • 一期管道藥物
    • 臨床前管道用藥
    • 早期研發管道藥物
    • 無用和過時的管道藥物
  • 按地區
  • 按照管理途徑
  • 按藥物類別
  • 按作用機制
  • 按分子類型
  • 按目標
  • 按公司類型

第8章管道藥物的概述和發展里程碑

  • 第三階段
    • ART-123 - ASAHI KASEI AMERICA
    • ZEMPIA - EXOXEMIS INC
    • REXIS - TAIRX INC
  • 第二階段
    • ADRECIZUMAB- ADRENOMED
    • RECOMBINANT HUMAN ALKALINE PHOSPHATASE (RECAP) - AM-PHARMA
    • METABLOK - ARCH BIOPARTNERS
    • NANGIBOTIDE (LR12) - INOTREM S.A
    • CYT107 - REVIMMUNE
    • SB-121 - SCIOTO BIOSCIENCES
    • CX611 - TIGENIX NV (ACQUIRED BY TAKEDA)
    • VBI-S - VIVACELLE BIO INC.
    • FETROJA (CEFIDEROCOL) - SHIONOGI & CO LTD
    • LB1148- LEADING BIOSCIENCES INC
  • 第一階段
    • ALLOCETRA - ENLIVEX THERAPEUTICS LTD.
    • STC3141 - CHINA GRAND PHARMACEUTICAL AND HEALTHCARE HOLDINGS LIMITED
    • VEYONDA (NOX66) - NOXOPHARM LIMITED
    • REJUVEINIX (RJX) - REVEN HOLDINGS, INC.
    • NUSEPIN - SHAPERON INC
    • NIVOLUMAB (BMS-936558) - BRISTOL-MYERS SQUIBB

第9章臨床試驗概述

  • 通過臨床測試結果進行分析
    • 第三階段
    • 第二階段
    • 第一階段
  • 正在進行的臨床試驗概述
  • 最近完成的臨床試驗摘要
  • 計劃中的臨床試驗大綱

第10章估計化膿性管線藥物的批准時間表

  • 調查方法
  • 在美國和美國以外的估計批准時間表

第11章通過競爭基準評估機會

  • 業務研發:內部投資和外部資金
  • 管道產品組合
  • 預期的市場准入
  • 專利和專有權
  • 營銷動態和合作夥伴關係
  • 取得特殊監管津貼
  • 企業發展

第12章當前和將來的競爭情況

  • 創業公司
    • 啟動配置文件
      • ENLIVEX THERAPEUTICS LTD。
      • AM-PHARMA
      • INOTREM S.A
      • VIVACELLE BIO,INC。
      • REVIMMUNE
      • ADRENOMED AG
      • SHAPERON,INC。
      • NOXOPHARM LTD。
      • PROTHERA BIOLOGICS,INC。
      • APTAHEM
目錄

GervanoRA's pipeline analysis and opportunity assessment report "Sepsis - Opportunity Assessments, Epidemiological Studies, Market Dynamics and Pipeline Analytics, H2 2020" analysed and assessed Sepsis pipeline molecules for the opportunities in the competitive space by covering all the pipeline molecules in different stages of development and all the companies which are actively involved in Sepsis drugs industry.

The report has been divided into segments like Disease Overview, Market Overview, Pipeline Analytics to provide in depth insights about the market dynamics and ongoing R&D in the Sepsis disease area. The report provides detailed insights about all the pipeline molecules in different stages of development and all the companies which are actively involved in Sepsis drugs industry. To provide systematic pipeline analytics, we have segregated total pipeline molecules into different segments like Pipeline Analytics by Stage of Development, Pipeline Analytics by Route of Administration, Pipeline Analytics by Geography, Pipeline Analytics by Mechanism of Action, Pipeline Analytics by Drug Class, Pipeline Analytics by Molecule Type, Pipeline Analytics by Molecule Target and Pipeline Analytics by Company Type.

Our comprehensive analysis on the Sepsis drug pipeline identified 70 drug candidates undergoing different stages of development- from Early R&D stage to Phase 3 stage. Among these, a total of nineteen (19) drug candidates are in clinical stages of development and 48 molecules are in non-clinical stage of development. The drug pipeline consists of three (03) pipeline molecules in late clinical stage of development (Phase 3), and a total of 06 pipeline molecules in early clinical stage of development (Phase 1). The report also aims to provide analytics and deep insights on the expected market share of the key Phase 3 and Phase 2 pipeline drugs for a better understanding of the Sepsis market in the coming years and know the competition which is paramount for any new entrant.

The report has covered more than 60 companies worldwide, involved in the development of new therapeutics. Growth opportunities in the report have been provided by performing a competitive and comparative analysis on the top 10 Emerging companies in the domain and hence deriving the key leader.

Report is more focused to provide competitive opportunities by assessing and providing in-depth analytics on:

  • Unmet needs and Opportunities
  • Market Dynamics with Coverage of Deals (Licensing, Partnering, Collaborations, Financing etc.)
  • Patent Analytics of Pipeline Molecules
  • Pipeline Analysis of all Drug Molecules and Estimated Pipeline Drug Approval Time lines of Late Clinical Stage (Phase 2 and Phase 3) Pipeline Drug Candidates
  • Clinical Stage Drug Candidates' Descriptions along with Development Milestones
  • Plotting of the Anticipated Market Share for the New Entrants (Phase 3 and Phase 2 Drugs)
  • Opportunity Assessments through Competitive Benchmarking
  • Evaluate Current and Future Competitive Landscape through Company Profiles
  • Emerging Company Profiles with Opportunity Assessments

Report helps clients to refine the commercial opportunities from the existing treatment armamentarium to pipeline assets, deals, and deal comparables. Even it helps in identifying the most relevant actors in the field for partnering deals.

TABLE OF CONTENTS

CHAPTER 01: INTRODUCTION

  • 1.1. REPORT DESCRIPTION
  • 1.2. METHODOLOGY
  • 1.3. ABOUT US: GERVANORA DATA SERVICES

CHAPTER 02: EXECUTIVE SUMMARY

  • 2.1. REPORT SUMMARY
  • 2.2. KEY EVENTS IN THE SEPSIS COMPETITIVE SPACE
  • 2.3. REPORT MAJOR FINDINGS
    • 2.3.1. DRIVERS
    • 2.3.2. RESTRAINTS
    • 2.3.3. OPPORTUNITIES
  • 2.4. MARKET DYNAMICS OF SEPSIS COMPETITIVE LANDSCAPE
    • 2.4.1. UNMET NEEDS AND MARKET DEMANDS FOR NEWER THERAPIES
    • 2.4.2. UNMET NEEDS AND MARKET DEMANDS BY ROUTE OF ADMINISTRATION (ROA)
    • 2.4.3. UNMET NEEDS AND MARKET DEMANDS BY GEOGRAPHY
    • 2.4.4. NEW DRUGS PRICING AND PRICING STRATEGIES
      • 2.4.4.1. ESTIMATED MARKET SHARE OF LATE CLINICAL STAGE PIPELINE DRUGS

CHAPTER 03: PIPELINE ANALYTICS OUTLOOK

  • 3.1. PIPELINE ANALYTICS COMPARATIVE SNAPSHOTS
    • 3.1.1. PIPELINE ANALYTICS COMPARATIVE SNAPSHOTS BY STAGE OF DEVELOPMENT
    • 3.1.2. PIPELINE ANALYTICS COMPARATIVE SNAPSHOTS BY GEOGRAPHY
    • 3.1.3. PIPELINE ANALYTICS COMPARATIVE SNAPSHOTS BY ROA
    • 3.1.4. PIPELINE ANALYTICS COMPARATIVE SNAPSHOTS BY DRUG CLASS
    • 3.1.5. PIPELINE ANALYTICS COMPARATIVE SNAPSHOTS BY MECHANISM OF ACTION
    • 3.1.6. PIPELINE ANALYTICS COMPARATIVE SNAPSHOTS BY MOLECULE TYPE
    • 3.1.7. PIPELINE ANALYTICS COMPARATIVE SNAPSHOTS BY MOLECULAR TARGET
    • 3.1.8. PIPELINE ANALYTICS COMPARATIVE SNAPSHOTS BY COMPANY TYPE

CHAPTER 04: SEPSIS THERAPIES OVERVIEW

  • 4.1. INTRODUCTION
  • 4.2. SEPSIS THERAPIES - DEVELOPMENT ASSESSMENTS
  • 4.3. SCOPE OF SEPSIS THERAPIES
  • 4.4. TREATMENT ALGORITHM AND GUIDELINES
  • 4.5. EPIDEMIOLOGY STUDIES
    • 4.5.1. GLOBAL AND HISTORICAL TRENDS

CHAPTER 05: MARKET DYNAMICS OF SEPSIS COMPETITIVE SPACE

  • 5.1. DEALS (MERGERS/ ACQUISITIONS/ COLLABORATIONS)
    • 5.1.1 DEALS ANALYTICS BY DEAL TYPE
      • 5.1.1.1. FINANCING DEALS
      • 5.1.1.2. COLLABORATION DEALS
      • 5.1.1.3. LICENSING DEALS
      • 5.1.1.4. MERGER AND ACQUISITION DEALS
    • 5.1.2 DEALS ANALYTICS BY ANNUAL FREQUENCY
    • 5.1.3 DEALS ANALYTICS BY ACTIVE PLAYERS

CHAPTER 06: PATENT ANALYTICS OF SEPSIS PIPELINE DRUGS

  • 6.1. PATENT ANALYTICS BY GEOGRAPHY
  • 6.2. PATENT ANALYTICS BY PATENT EXPIRY
  • 6.3. PATENT ANALYTICS BY SPECIAL ALLOWANCES AND TERM EXTENSIONS

CHAPTER 07: PIPELINE DRUGS ANALYTICS OF SEPSIS

  • 7.1. PIPELINE DRUGS ANALYTICS BY STAGE OF DEVELOPMENT
    • 7.1.1. PHASE III PIPELINE DRUGS
    • 7.1.2. PHASE II PIPELINE DRUGS
    • 7.1.3. PHASE I PIPELINE DRUGS
    • 7.1.4. PRECLINICAL PIPELINE DRUGS
    • 7.1.5. EARLY R&D PIPELINE DRUGS
    • 7.1.6. INACTIVE AND DISCONTINUED PIPELINE DRUGS
  • 7.2. PIPELINE DRUGS ANALYTICS BY GEOGRAPHY
  • 7.3. PIPELINE DRUGS ANALYTICS BY ROUTE OF ADMINISTRATION
  • 7.4. PIPELINE DRUGS ANALYTICS BY DRUG CLASS
  • 7.5. PIPELINE DRUGS ANALYTICS BY MECHANISM OF ACTION
  • 7.6. PIPELINE DRUGS ANALYTICS BY MOLECULE TYPE
  • 7.7. PIPELINE DRUGS ANALYTICS BY TARGET
  • 7.8. PIPELINE DRUGS ANALYTICS BY COMPANY TYPE

CHAPTER 08: PIPELINE DRUGS DESCRIPTIONS AND DEVELOPMENT MILESTONES

  • 8.1. PHASE III PIPELINE DRUGS DESCRIPTIONS AND DEVELOPMENT MILESTONES
    • 8.1.1. ART-123 - ASAHI KASEI AMERICA
    • 8.1.2. ZEMPIA - EXOXEMIS INC
    • 8.1.3. REXIS - TAIRX INC
  • 8.2. PHASE II PIPELINE DRUGS DESCRIPTIONS AND DEVELOPMENT MILESTONES
    • 8.2.1. ADRECIZUMAB- ADRENOMED
    • 8.2.2. RECOMBINANT HUMAN ALKALINE PHOSPHATASE (RECAP) - AM-PHARMA
    • 8.2.3. METABLOK - ARCH BIOPARTNERS
    • 8.2.4. NANGIBOTIDE (LR12) - INOTREM S.A
    • 8.2.5. CYT107 - REVIMMUNE
    • 8.2.6. SB-121 - SCIOTO BIOSCIENCES
    • 8.2.7. CX611 - TIGENIX NV (ACQUIRED BY TAKEDA)
    • 8.2.8. VBI-S - VIVACELLE BIO INC.
    • 8.2.9. FETROJA (CEFIDEROCOL) - SHIONOGI & CO LTD
    • 8.2.10. LB1148- LEADING BIOSCIENCES INC
  • 8.3. PHASE I PIPELINE DRUGS DESCRIPTIONS AND DEVELOPMENT MILESTONES
    • 8.3.1. ALLOCETRA - ENLIVEX THERAPEUTICS LTD.
    • 8.3.2. STC3141 - CHINA GRAND PHARMACEUTICAL AND HEALTHCARE HOLDINGS LIMITED
    • 8.3.3. VEYONDA (NOX66) - NOXOPHARM LIMITED
    • 8.3.4. REJUVEINIX (RJX) - REVEN HOLDINGS, INC.
    • 8.3.5. NUSEPIN - SHAPERON INC
    • 8.3.6. NIVOLUMAB (BMS-936558) - BRISTOL-MYERS SQUIBB

CHAPTER 09: CLINICAL TRIALS SUMMARY

  • 9.1. ANALYSIS BY CLINICAL TRIAL RESULTS
    • 9.1.1. KEY PHASE 3 CLINICAL TRIAL RESULTS
    • 9.1.2. KEY PHASE 2 CLINICAL TRIAL RESULTS
    • 9.1.3. KEY PHASE 1 CLINICAL TRIAL RESULTS
  • 9.2. ONGOING CLINICAL TRIALS SUMMARY
    • 9.2.1. PHASE 3 ONGOING CLINICAL TRIALS SUMMARY
    • 9.2.2. PHASE 2 ONGOING CLINICAL TRIALS SUMMARY
    • 9.2.3. PHASE 1 ONGOING CLINICAL TRIALS SUMMARY
  • 9.3. RECENTLY COMPLETED CLINICAL TRIALS SUMMARY
    • 9.3.1. RECENTLY COMPLETED PHASE 3 CLINICAL TRIALS
    • 9.3.2. RECENTLY COMPLETED PHASE 2 CLINICAL TRIALS
    • 9.3.3. RECENTLY COMPLETED PHASE 1 CLINICAL TRIALS
  • 9.4. PLANNED CLINICAL TRIALS SUMMARY

CHAPTER 10: ESTIMATED APPROVAL TIMELINES OF SEPSIS PIPELINE DRUGS

  • 10.1. METHODOLOGY
  • 10.2. ESTIMATED APPROVAL TIMELINES US & EX-US

CHAPTER 11: OPPORTUNITY ASSESSMENTS THROUGH COMPETITIVE BENCH-MARKING

  • 11.1. BUSINESS R&D - INTERNAL INVESTMENT AND EXTERNAL FUNDING
  • 11.2. PIPELINE PORTFOLIO
  • 11.3. EXPECTED MARKET ENTRIES
  • 11.4. PATENTS AND EXCLUSIVITY
  • 11.5. MARKETING DYNAMICS AND PARTNERING
  • 11.6. ACHIEVEMENTS OF SPECIAL REGULATORY ALLOWANCES
  • 11.7. COMPANY DEVELOPMENTS

CHAPTER 12: CURRENT AND FUTURE COMPETITIVE LANDSCAPE

  • 12.1: EMERGING COMPANIES
    • 12.1.1 EMERGING COMPANY PROFILES
      • 12.1.1.1: ENLIVEX THERAPEUTICS LTD.
      • 12.1.1.2: AM-PHARMA
      • 12.1.1.3: INOTREM S.A
      • 12.1.1.4: VIVACELLE BIO, INC.
      • 12.1.1.5: REVIMMUNE
      • 12.1.1.6: ADRENOMED AG
      • 12.1.1.7: SHAPERON, INC.
      • 12.1.1.8: NOXOPHARM LTD.
      • 12.1.1.9: PROTHERA BIOLOGICS, INC.
      • 12.1.1.10: APTAHEM

LIST OF TABLES

  • TABLE 01: SEPSIS REPORT HIGHLIGHTS IN NUMERICALS
  • TABLE 02: CLASSIFICATION OF SEPSIS
  • TABLE 03: SEPSIS APPROVED DRUGS
  • TABLE 04: INCIDENT RATES OF HOSPITAL TREATED SEVERE SEPSIS ACROSS EUROPEAN REGIONS
  • TABLE 05: FINANCING DEALS IN SEPSIS THERAPEUTIC AREA
  • TABLE 06: COLLABORATION DEALS IN SEPSIS THERAPEUTIC AREA
  • TABLE 07: LICENSING DEALS IN SEPSIS THERAPEUTIC AREA
  • TABLE 08: MERGER AND ACQUISITION DEALS IN SEPSIS THERAPEUTIC AREA
  • TABLE 09: PATENT FAMILIES OWNED BY VIVACELLE BIO
  • TABLE 10: PATENT FAMILIES OWNED BY SHAPERON
  • TABLE 11: PATENT FAMILIES OWNED BY NOXOPHARM
  • TABLE 12: PATENTS AND PATENT APPLICATIONS OF ADRENOMED WITH RESPECT TO ADRECIZUMAB
  • TABLE 13: PATENT PORTFOLIO OWNED BY APTAHEM WITH RESPECT APT-1
  • TABLE 14: SEPSIS PIPELINE DRUGS BY STAGE OF DEVELOPMENT
  • TABLE 15: SEPSIS PHASE III PIPELINE MOLECULES
  • TABLE 16: SEPSIS PHASE II PIPELINE MOLECULES
  • TABLE 17: SEPSIS PHASE I PIPELINE MOLECULES
  • TABLE 18: SEPSIS PRECLINICAL PIPELINE MOLECULES
  • TABLE 19: SEPSIS EARLY R&D PIPELINE MOLECULES
  • TABLE 20: INACTIVE AND DISCONTINUED MOLECULES IN SEPSIS
  • TABLE 21: LIST OF PIPELINE MOLECULES WITH PARENTERAL ROUTE OF ADMINISTRATION
  • TABLE 22: LIST OF PIPELINE MOLECULES WITH ORAL ROUTE OF ADMINISTRATION
  • TABLE 23: ANTI-INFLAMMATORY DRUGS UNDER DEVELOPMENT
  • TABLE 24: IMMUNOMODULATORY DRUGS UNDER DEVELOPMENT
  • TABLE 25: CELL-BASED THERAPIES UNDER DEVELOPMENT
  • TABLE 26: PEPTIDE-BASED THERAPIES UNDER DEVELOPMENT
  • TABLE 27: PROTEIN ACTIVATORS AND INHIBITORS UNDER DEVELOPMENT
  • TABLE 28: LIST OF SEPSIS PIPELINE MOLECULES WITH THEIR MECHANISM OF ACTIONS
  • TABLE 29: LIST OF COMPANIES DEVELOPING BIOLOGIC DRUGS
  • TABLE 30: LIST OF PIPELINE MOLECULES WITH THE MOLECULE TARGET
  • TABLE 31: SEPSIS PIPELINE DRUGS ANALYTICS BY COMPANY TYPE
  • TABLE 32: REGION WISE STATISTICS, COMPANY COUNT OF SEPSIS THERAPEUTICS
  • TABLE 33: ONO PHARMACEUTICAL CO., LTD' ONOACT PHASE III TRIAL DESIGN
  • TABLE 34: ASAHI KASEI PHARMA AMERICA CORPORATION'S ART-123 PHASE 3 TRIAL DESIGN
  • TABLE 35: AM-PHARMA'S RECAP PHASE 2 TRIAL DESIGN
  • TABLE 36: ADRENOMED AG'S ADRECIZUMAB PHASE 2 TRIAL DESIGN
  • TABLE 37: ENLIVEX'S ALLOCETRA PHASE I TRIAL DESIGN
  • TABLE 38: PHASE 2 ONGOING CLINICAL TRIALS
  • TABLE 39: PHASE 1 ONGOING CLINICAL TRIALS
  • TABLE 40: PHASE 3 ONGOING CLINICAL TRIALS
  • TABLE 41: PHASE 2 RECENTLY COMPLETED CLINICAL TRIALS
  • TABLE 42: PHASE 1 RECENTLY COMPLETED CLINICAL TRIALS
  • TABLE 43: PLANNED CLINICAL TRIALS
  • TABLE 44: GERVANORA ESTIMATED APPROVAL TIMELINES V/S ACTUAL APPROVAL DATE
  • TABLE 45: ESTIMATED APPROVAL TIMELINES OF PHASE 3 AND PHASE 2 DRUG CANDIDATES
  • TABLE 46: PIPELINE ASSETS OF ENLIVEX THERAPEUTICS
  • TABLE 47: PIPELINE ASSETS OF AM-PHARMA
  • TABLE 48: PATENTS AND PATENT APPLICATIONS OF AM-PHARMA
  • TABLE 49: PIPELINE ASSETS OF INOTREM
  • TABLE 50: PATENTS AND PATENT APPLICATIONS OF VIVACELLE BIO FILED IN THE U.S AND CANADA
  • TABLE 51: PATENTS & PATENT APPLICATIONS OF VIVACELLE BIO FILED IN COUNTRIES OTHER THAN THE U.S & CANADA
  • TABLE 52: PIPELINE ASSETS OF REVIMMUNE WITH RESPECT TO INFECTIOUS DISEASES
  • TABLE 53: PIPELINE ASSETS OF REVIMMUNE WITH RESPECT TO ONCOLOGY
  • TABLE 54: PATENTS AND PATENT APPLICATIONS OF REVIMMUNE
  • TABLE 55: PATENTS AND PATENT APPLICATIONS OF ADRENOMED
  • TABLE 56: PIPELINE ASSETS OF SHAPERON
  • TABLE 57: PATENTS AND PATENT APPLICATIONS OF SHAPERON
  • TABLE 58: PIPELINE ASSETS OF NOXOPHARM
  • TABLE 59: PATENTS AND PATENT APPLICATIONS OF NOXOPHARM
  • TABLE 60: PATENTS AND PATENT APPLICATIONS OF PROTHERA BIOLOGICS FILED IN THE U.S AND CANADA
  • TABLE 61: PATENTS AND PATENT APPLICATIONS OF PROTHERA BIOLOGICS FILED IN COUNTRIES OTHER THAN THE U.S
  • TABLE 62: PIPELINE ASSETS OF APTAHEM
  • TABLE 63: PATENT PORTFOLIO OWNED BY APTAHEM

LIST OF FIGURES

  • FIGURE 01: KEY EVENTS IN THE SEPSIS COMPETITIVE SPACE
  • FIGURE 02: SEPSIS TOTAL MARKET SHARE
  • FIGURE 03: COMPARISON OF SEPSIS MARKET SHARE, 2023 VERSUS 2027
  • FIGURE 04: ZEMPIA EXPECTED MARKET SHARE IN 2023
  • FIGURE 05: COMPARISON OF EXPECTED PEAK SALES OF ZEMPIA, ART-123 AND REXIS
  • FIGURE 06: ESTIMATED MARKET SHARE (%) OVERVIEW IN 2023
  • FIGURE 07: ESTIMATED MARKET SHARE (%) OVERVIEW IN 2024
  • FIGURE 08: ESTIMATED MARKET SHARE (%) OVERVIEW IN 2025
  • FIGURE 09: ESTIMATED MARKET SHARE (%) OVERVIEW IN 2027
  • FIGURE 10: SEPSIS DRUG PIPELINE SCENARIO, COMPANY TYPE AND DRUG CANDIDATES WRT HSD
  • FIGURE 11: COMPARISON OF GLOBAL INCIDENT CASES (IN MILLIONS), 1990 V/S 2017
  • FIGURE 12: COMPARISON OF GLOBAL INCIDENCE AND MORTALITY IN THE YEAR 2017
  • FIGURE 13: INCIDENT CASES IN THE US AS PER EPIDEMIOLOGICAL STUDIES CONDUCTED
  • FIGURE 14: TREND IN SEPSIS INCIDENT RATES IN THE US (PER 100,000 PEOPLE)
  • FIGURE 15: SEPSIS-ASSOCIATED MORTALITY, BY TYPE OF CAUSE OF DEATH
  • FIGURE 16: SEPSIS INCIDENT RATES TREND
  • FIGURE 17: INCIDENT RATES AND MORTALITY RATES OF SEPSIS IN AUSTRALIA
  • FIGURE 18: SEPSIS DEAL ANALYTICS BY DEAL TYPE
  • FIGURE 19: SEPSIS DEAL ANALYTICS BY DEAL FREQUENCY
  • FIGURE 20: DEAL TYPE BREAKDOWN FOR THE YEAR OF 2020
  • FIGURE 21: DEALS ANALYTICS BY ACTIVE PLAYERS IN SEPSIS MARKET
  • FIGURE 22: BREAKDOWN OF PATENTS FILED ACROSS THE GLOBE FOR SEPSIS TREATMENT
  • FIGURE 23: GEOGRAPHICAL DISTRIBUTION OF PATENTS AND PATENT FAMILIES OWNED BY ENLIVEX THERAPEUTICS
  • FIGURE 24: GEOGRAPHICAL DISTRIBUTION OF PATENTS AND PATENT FAMILIES OWNED BY AM-PHARMA
  • FIGURE 25: GRAPHICAL REPRESENTATION OF PATENTS AND PATENT FAMILIES OWNED BY REVIMMUNE
  • FIGURE 26: GRAPHICAL REPRESENTATION OF PATENTS AND PATENT FAMILIES OWNED BY ADRENOMED
  • FIGURE 27: GRAPHICAL REPRESENTATION OF PATENTS AND PATENT FAMILIES OWNED BY PROTHERA BIOLOGICS
  • FIGURE 28: PIPELINE MOLECULES - CLINICAL VS PRECLINICAL & EARLY R&D
  • FIGURE 29: TOTAL PIPELINE MOLECULES VS STAGE OF DEVELOPMENT
  • FIGURE 30: SCHEMATIC REPRESENTATION OF SEPSIS WORLDWIDE ANTICIPATED DRUG APPROVALS
  • FIGURE 31: GRAPHICAL REPRESENTATION OF SEPSIS PIPELINE DRUGS FOR APPROVAL REGIONS & HSD
  • FIGURE 32: SEPSIS DRUGS PIPELINE ANALYTICS BY ROA
  • FIGURE 33: SEPSIS DRUGS PIPELINE ANALYTICS BY PARENTERAL ROA
  • FIGURE 34: PARENTERAL DRUGS PIPELINE ANALYTICS BY STAGE OF DEVELOPMENT
  • FIGURE 35: TOTAL PIPELINE MOLECULES V/S DRUG CLASSES
  • FIGURE 36: LIST OF COMPANIES WITH RESPECT TO THE DRUG CLASSES
  • FIGURE 37: PIPELINE DRUG CLASS ANALYTICS BY STAGE OF DEVELOPMENT
  • FIGURE 38: SCENARIO OF SEPSIS DRUG PIPELINE, MOA AND STAGE OF DEVELOPMENT
  • FIGURE 39: SEPSIS PIPELINE DRUGS BIOLOGICALS VS SMALL MOLECULES
  • FIGURE 40: MOLECULE TYPE PIPELINE ANALYTICS BY STAGE OF DEVELOPMENT
  • FIGURE 41: HSD WISE REPRESENTATION OF MORE COMMON DRUG TARGETS
  • FIGURE 42: SEPSIS PIPELINE DRUG ANALYTICS BY COMPANY TYPE
  • FIGURE 43: COMPANIES WORKING ON SEPSIS TYPE THERAPIES (BY COMPANY TYPE)
  • FIGURE 44: GEOGRAPHICAL CATEGORIZATION OF COMPANIES WORKING ON SEPSIS THERAPEUTICS
  • FIGURE 45: HEART RATE, ADVERSE EVENTS & SERIOUS ADVERSE EVENTS PARAMETERS FOR LANDIOLOL & PLACEBO
  • FIGURE 46: MORTALITY RATE AND SERIOUS ADVERSE EVENTS MEASURED PARAMETERS FOR ART-123 AND PLACEBO
  • FIGURE 47: AUC 1-7 AND MORTALITY RATE AT DAY 28 AND DAY 90 MEASURED PARAMETERS FOR RECAP AND PLACEBO
  • FIGURE 48: MORTALITY RATE AT DAY 14 AND DAY 28 MEASURED PARAMETERS FOR ADRENOSS-2
  • FIGURE 49: SOFA SCORE MEASURED PARAMETERS FOR ALLOCETRA
  • FIGURE 50: MORTALITY RATE AT DAY 28 FOR ALLOCETRA
  • FIGURE 51: CLINICAL TRIAL SUMMARY OF ONGOING PHASE II CLINICAL TRIALS
  • FIGURE 52: CLINICAL TRIAL SUMMARY OF ONGOING PHASE I CLINICAL TRIALS
  • FIGURE 53: CLINICAL TRIAL SUMMARY OF RECENTLY COMPLETED PHASE II CLINICAL TRIALS
  • FIGURE 54: CLINICAL TRIAL SUMMARY OF RECENTLY COMPLETED PHASE I CLINICAL TRIALS
  • FIGURE 55: PIPELINE PORTFOLIO WITH (NUMBER OF MOLECULES)
  • FIGURE 56: EXPECTED MARKET ENTRY WITH RESPECT TO PRODUCT CANDIDATES FOR SEPSIS
  • FIGURE 57: TIME LINE OF PATENT AND PATENT APPLICATION EXPIRIES WITH RESPECT TO TREATMENT OF SEPSIS
  • FIGURE 58: RANKING TOP 5 EMERGING COMPANIES BASED ON THE PARTNERING ACTIVITIES
  • FIGURE 59: GLOBAL PRESENCE OF ENLIVEX THERAPEUTICS
  • FIGURE 60: DRUG DEVELOPMENT MILESTONES OF ENLIVEX THERAPEUTICS
  • FIGURE 61: DRUG DEVELOPMENT MILESTONES OF AM-PHARMA WITH RESPECT TO RECAP FOR TREATMENT OF SA-AKI
  • FIGURE 62: AREAS OF TREATMENT OF AM-PHARMA
  • FIGURE 63: PARTNERSHIPS OF INOTREM
  • FIGURE 64: DRUG DEVELOPMENT MILESTONES OF INOTREM
  • FIGURE 65: DRUG DEVELOPMENT MILESTONES OF VIVACELLE BIO
  • FIGURE 66: GLOBAL PRESENCE OF REVIMMUNE
  • FIGURE 67: KEY ACADEMIC PARTNERSHIPS OF REVIMMUNE
  • FIGURE 68: AREAS OF TREATMENT OF REVIMMUNE
  • FIGURE 69: ADRENOMED'S INVESTORS
  • FIGURE 70: DRUG DEVELOPMENT MILESTONES OF ADRENOMED
  • FIGURE 71: GLOBAL PRESENCE OF NOXOPHARM